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CD137 (also known as 4-1BB and TNFRSF9) is a mem-
ber of the tumor necrosis factor receptor superfamily.
Originally identified as a costimulatory molecule ex-
pressed by activated T cells and NK cells, CD137 is
also expressed by follicular dendritic cells, mono-
cytes, mast cells, granulocytes, and endothelial cells.
Anti-CD137 immunotherapy has recently shown
promise as a treatment for solid tumors and lym-
phoid malignancies in preclinical models. We defined
the expression of CD137 protein in both normal and
neoplastic hematolymphoid tissue. CD137 protein is
expressed by follicular dendritic cells in the germinal
center and scattered paracortical T cells, but not by
normal germinal-center B cells, bonemarrow progen-
itor cells, or maturing thymocytes. CD137 protein is
expressed by a select group of hematolymphoid tu-
mors, including classical Hodgkin lymphoma, T-cell
and NK/T-cell lymphomas, and follicular dendritic
cells neoplasms. CD137 is a novel diagnostic marker
of these tumors and suggests a possible target for
tumor-directed antibody therapy. (Am J Pathol 2012,
181:795–803; http://dx.doi.org/10.1016/j.ajpath.2012.05.015)CD137 (also known as 4-1BB and TNFRSF9) is a trans-
membrane glycoprotein of the tumor necrosis factor re-
ceptor superfamily. CD137 is broadly expressed by cells
of the human immune system, including activated CD8
and CD4 T cells, activated natural killer (NK) cells, fol-
licular dendritic cells (FDCs), monocytes, and a minor
subpopulation of activated B cells within the germinal
center (GC).1–7 CD137 can also be expressed by mes-
enchymal cells, including endothelial cells, chondro-
cytes, and cells of the central nervous system.8–10 Al-
though CD137 has diverse roles in the immune response,
one key function is to promote the survival of both T cells
and dendritic cells by binding the cognate ligand
CD137L (4-1BBL).11 In T cells and FDCs, engagement of
CD137 by CD137L leads to activation of the NF-B path-
way and up-regulation of antiapoptotic members of the
Bcl-2 family including Bfl-1 and Bcl-XL.
12,13 In addition to
prosurvival signals, CD137 expression by FDCs has
been shown to promote T-cell-dependent humoral im-
mune responses by stimulating the proliferation of GC T
and B cells.7,14
Given the important role of CD137 in providing co-
stimulatory and prosurvival signals, the use of anti-CD137
antibodies as a therapeutic strategy for both solid-organ
and hematolymphoid malignancies has been the subject
of intense investigation.15 Preclinical data using agonistic
blocking anti-CD137 antibodies has shown promising an-
titumor efficacy in mouse models of sarcoma, mastocy-
toma, and plasma cell myeloma.16,17 More recently,
members of our research group demonstrated that ago-
nistic antibodies to CD137 could also eradicate estab-
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tumor effect of the agonistic anti-CD137 antibody was
shown to be mediated by NK cells and CD8 T cells,
because the lymphoma cells did not express CD137.
Also, in tumor samples that included both tumor cells and
infiltrating immune cells, the expression of the mRNA
encoding CD137 (TNFRSF9) and a marker of germinal-
center B cells (LMO2) predicted outcome in patients with
diffuse large B-cell lymphoma (DLBCL).19 The prognostic
effect of CD137 was contributed by the tumor microen-
vironment and likely correlates with the frequency of an
activated T-cell subset, because no correlation was seen
between CD137 expression and total T-cell infiltration
within tumors. Although the precise mechanism of the
antitumor effect of CD137 immunomodulation remains
unclear, there is evidence to suggest that CD137 expres-
sion by dendritic cells and intratumoral blood vessels
may also play a role in the antitumor effect of CD137.20–23
In contrast to the well-characterized expression of
CD137 by normal immune-cell subsets, the expression of
CD137 by neoplastic hematolymphoid cells is poorly un-
derstood. CD137 expression is inducible in human T-cell
leukemia cell lines in vitro,1,24 but few data have been
available on the expression pattern of CD137 in primary
human hematolymphoid tumors. In the present study, we
characterized CD137 expression in normal and neoplas-
tic hematolymphoid tissue through the use of immunohis-
tochemistry and immunofluorescence on tissue sections
and cell suspensions.
Materials and Methods
Tissue Samples
Formalin-fixed, paraffin-embedded tissue samples were
obtained from the archives of the Department of Pathol-
ogy, Stanford University Medical Center (SUMC). Tissue
microarrays (TMAs) incorporating SUMC pathological
material were constructed as described previously.25
TMAs encompassing 265 cases of classical Hodgkin
lymphoma from the Federal University of Rio de Janeiro
were also used.26 All tissues were obtained before treat-
ment, and Institutional Review Board approval was ob-
tained for the study. For expression in normal hematopoi-
etic tissue, whole-tissue sections of normal human
spleen, thymus, bone marrow, and tonsil were used. He-
matolymphoid neoplasia was classified according to the
current, 2008 World Health Organization (WHO) classifi-
cation.27
Immunohistochemistry
TMAs, whole sections of human lymphoma and leukemia
samples, and normal human hematopoietic tissue sam-
ples were sectioned at 0.4-m thickness, deparaffinized
in xylene, and hydrated in graduated alcohols. Slides
were pretreated with 10 mmol/L citrate buffer (pH 6.0).
Slides were then stained with anti-CD137 antibody (clone
BBK-2; Thermo Scientific, Fremont, CA) at 1:30 dilution.
Multiple different commercially available antibodies were
tested, but the most consistent staining results were ob-tained with clone BBK-2. Slides were developed using
the Dako Envision method (Dako, Carpinteria, CA) and
were coverslipped with aqueous-based mounting me-
dium. Immunohistologic staining for CD20 (L26, dilution
1:1000; Dako), CD3 (rabbit polyclonal, dilution 1:50; Cell
Marque, Rocklin, CA), CD21 (IF8, dilution 1:20; Dako),
CD23 (1B12, dilution 1:50; Novocastra Laboratories,
Newcastle upon Tyne, UK), CD4 (IF6, dilution 1:20; No-
vocastra Laboratories), CD8 (C8/144B, dilution 1:200;
Dako), CD30 (BerH2, dilution 1:40; Dako), CD15 (Carb3,
dilution 1:250; Dako), and ALK1 (clone ALK1, dilution
1:75; Dako) were performed on a BenchMark XT (Ven-
tana Medical Systems, Tucson, AZ), or a Leica Bond-Max
(Leica Microsystems, Buffalo Grove, IL; Wetzlar, Ger-
many) automated immunostainer, using standard re-
trieval conditions. In situ hybridization with the EBER
probe was performed using an INFORM EBER kit on a
BenchMark XT immunostainer (Ventana Medical Sys-
tems). Stains for CD21 and CD23 were performed on
sections of normal tonsil and histiocytic/dendritic cell
neoplasms, whereas stains for CD30, CD15, and EBER
were performed on a TMA composed of classical Hodg-
kin lymphoma cases. The remaining immunohistochemi-
cal stains (CD3, CD4, CD8, CD20, and ALK1) were per-
formed to further characterize select T-cell lymphoma
cases. TMAs were scored as 0  no staining, 1  unin-
terpretable (loss of sample tissue or high background),
2  weak staining (5% to 20% of cells positive), and 3 
strong staining (20% of cells positive). For the immuno-
histochemistry data on tumor cell expression of CD137
(Table 1), cases were scored positive if 5% of the
lesional cells stained positive for CD137. Each sample
was independently scored by three pathologists (Y.N.,
M.W.A., and A.G.F.), with a concordance rate of 98%.
Discrepant cases were jointly reviewed using a multi-
headed microscope and a final score was assigned.
Immunofluorescence
Paraffin-embedded whole-tissue sections of normal hu-
man tonsil (n  12), classical Hodgkin lymphoma (n 
10), peripheral T-cell lymphoma not otherwise specified
(PTCL NOS) (n  3), and angioimmunoblastic T-cell lym-
phoma (AITL) (n 1) were sectioned at 0.4-m thickness
and deparaffinized; microwave-induced antigen retrieval
was performed in 0.1 mol/L sodium citrate (pH 6.0).
Slides were then stained with mixtures of two of three
primary antibodies [CD137 (mouse anti-human) (1:30 di-
lution; Thermo Scientific, Fremont, CA), CD3 (rabbit anti-
human) (1:100 dilution; Cell Marque), and Oct-2 (1:100
dilution; Santa Cruz Biotechnology, Santa Cruz, CA)].
Slides were then washed in PBS (pH 7.5) and incubated
in the dark for 30 minutes with a mixture of two secondary
antibodies: goat anti-mouse IgG labeled with Alexa Fluor
568 and goat anti-rabbit IgG labeled with Alexa Fluor 488
(Invitrogen, Carlsbad, CA). Slides were then washed in
PBS (pH 7.5) and counterstained by incubation with
Vectashield DAPI (Vector Laboratories, Burlingame, CA).
The slides were then coverslipped with an aqueous-
based mounting medium.
*Referred to in the text as BCLU/DLBCL/CHL.
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Expression of CD137 on the surface of lymphoid cells
from normal tonsil (n  2) and from T-cell lymphoma
samples (n  4) was determined using antibodies
against CD20 FITC, CD3 Pacific Blue, CD4 PerCP, CD8
APC-H7, CD45RO PE-Cy7, and CD137 PE (Pharmingen;
BD Biosciences, San Jose, CA), according to standard
protocols for surface staining. Cells were interrogated on
an LSR II flow cytometer using FACSDiva software (BD
Biosciences), and data were analyzed via Cytobank web-
based software (http://www.cytobank.org).
Data Analysis and Visualization
Images of normal human hematolymphoid tissue and
TMA immunohistochemical staining results were ac-
quired using a Nikon Eclipse E1000 microscope (Nikon,
Tokyo, Japan) equipped with 4, 10, 20, 40, and
60 objective lenses with numerical apertures ranging
from 0.05 to 0.90. Images were captured with a SPOT
Flex mosaic digital camera (imaging area, 15.2  15.2
mm) and SPOT Basic software (SPOT Imaging Solutions;
Diagnostic Instruments, Sterling Heights, MI). Immunoflu-
orescence images were acquired using a Nikon Eclipse
E800 microscope and a DXM1200C Nikon digital cam-
era. Digitized images were processed using Adobe Illus-
trator software (Adobe Systems, San Jose, CA). Confocal
images were obtained using a Nikon D-Eclipse C1
confocal system and processed with Nikon EZ-C1 3.90
software and Adobe Photoshop software. The stained
lymphoma TMA slides were scanned and stored as high-
resolution images using an automated slide scanner
(Bacus Laboratories; Olympus, Center Valley, PA). Im-
ages of primary TMA staining data are available online
(http://tma.stanford.edu/tma_portal/CD137).
Results
CD137 Protein Is Expressed by FDCs in Normal
Hematolymphoid Tissue
To define the expression pattern of CD137 protein in
normal human lymphoid tissue, we performed immuno-
fluorescence microscopy on paraffin-embedded tissue
sections of normal tonsil. Antibodies to CD3 and the
B-cell transcription factor OCT-2 highlighted a normal
tonsillar immunoarchitecture of T-cell-rich interfollicular
zones and B cells localized predominantly to the GC and
mantle zone (Figure 1, A and B). Antibody to CD137
highlighted spindled-appearing cells localized exclu-
sively to the GC, morphologically consistent with FDCs
(Figure 1, A and B, insets). Although rare T cells in the
interfollicular zones coexpressed CD137, we did not ob-
serve expression of CD137 by either GC T cells (Figure
1A, inset) or by OCT-2-expressing GC B cells (Figure
1B). Consistent with prior reports,5,7 these results sug-
gested that CD137 expression is restricted to FDCs in
normal human tonsil. To confirm the expression of CD137Table 1. Tumor Cell Expression of CD137 Protein Determined
by Immunohistochemistry
Tumor subtype
Total
positive
(n/N)
%
Positive
Histiocytic and dendritic cell
neoplasms (n  23)
6/23 26
Follicular dendritic cell sarcoma 6/7 86
Interdigitating dendritic cell tumor 0/1 0
Langerhans cell histiocytosis 0/10 0
Rosai-Dorfman disease 0/3 0
Histiocytic sarcoma 0/2 0
Hodgkin lymphoma (n  225) 179/225 80
Classical Hodgkin lymphoma (CHL) 179/208 86
Nodular lymphocyte predominant
Hodgkin lymphoma (NLPHL)
0/17 0
T-cell lymphoma (n  80) 46/80 58
T-lymphoblastic lymphoma/leukemia 0/7 0
Peripheral T-cell lymphoma, not
otherwise specified (PTCL NOS)
9/16 56
Angioimmunoblastic T-cell
lymphoma (AITL)
18/32 56
Mycosis fungoides 6/7 86
Large T-cell lymphoma, transformed
from mycosis fungoides
7/9 78
Subcutaneous panniculitis-like T-cell
lymphoma
1/1 100
Anaplastic large cell lymphoma
(ALK and ALK)
5/8 63
Extranodal NK/T-cell lymphoma, nasal
type
34/93 37
B-cell lymphoma (n  359) 12/359 3
Follicular lymphoma 0/134 0
Grade 1 and 2 0/84 0
Grade 3A and 3B 0/50 0
Diffuse large B-cell lymphoma
(DLBCL)
0/95 0
Primary mediastinal large B-cell
lymphoma (PMBL)
7/46 15
B-cell lymphoma, unclassifiable
(features intermediate between
DLBCL and CHL)*
5/10 50
Burkitt’s lymphoma 0/3 0
Extranodal marginal zone lymphoma 0/10 0
Splenic marginal zone lymphoma 0/5 0
Nodal marginal zone lymphoma 0/3 0
Mantle cell lymphoma 0/12 0
Chronic lymphocytic leukemia/small
cell lymphocytic leukemia (CLL/
SLL)
0/30 0
Lymphoplasmacytic lymphoma 0/4 0
B-lymphoblastic lymphoma/leukemia 0/5 0
Post-transplant lymphoproliferative
disorder
0/2 0
Plasma cell neoplasms (n  158) 0/158 0
Monoclonal gammopathy of
undetermined significance
(MGUS)
0/8 0
Multiple myeloma 0/131 0
Plasma cell leukemia 0/11 0
Plasmacytoma 0/8 0
Other (n  17)
Systemic mast cell disease 0/2 0
Acute myeloid leukemia (various
WHO subtypes)
0/11 0
Blastic plasmacytoid dendritic cell
neoplasm
1/4 25by FDCs, sections of normal tonsil were also stained with
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FDCs.28 Indeed, tonsillar GCs showed identical patterns
of immunohistochemical reactivity using antibodies to ei-
ther CD137 or CD21, suggesting that CD137 is a specific
marker of FDCs (Figure 1, C and D).
Next, we investigated CD137 protein expression in
normal human thymus, spleen, and bone marrow using
immunohistochemistry. In normal human thymus, only
rare cells within the thymic medulla expressed CD137
protein (Figure 1E). No expression of CD137 was de-
tected in the thymic cortex, suggesting that neither im-
mature T cells nor thymic epithelial cells express CD137.
In normal human spleen, CD137 expression was re-
stricted to spindled cells with morphological features of
FDCs within GCs of the white pulp (Figure 1F); CD137
expression was not detected within the mantle zones or
red pulp. Sections of normal human bone marrow
showed an absence of CD137 staining in hematopoietic
precursors and in bone marrow stromal elements (data
not shown).
To evaluate the expression of CD137 in nonhema-
tolymphoid tissue, a TMA containing samples from 61
cases of both normal and neoplastic tissues derived from
human skin, soft tissue, placenta, skeletal muscle, heart,
Figure 1. Expression of CD137 protein in normal human hematopoietic
tissues. A: Section of normal reactive human tonsil stained with antibodies to
CD137 (red; cytoplasm and cell membrane) and CD3 (green; cell mem-
brane). DAPI (blue) was used as a nuclear counterstain. B: Section of normal
reactive human tonsil stained with antibodies to CD137 (red) and OCT-2
(green; nuclear). C: Section of normal human tonsil stained with antibody to
CD21. D: Section of normal human tonsil stained with antibody to CD137. E:
Section of normal human thymus stained with anti-CD137 antibody. F:
Section of normal human spleen stained with anti-CD137 antibody. Original
magnification: 100 (A); 400 (B–D); 200 (E and F); 600 (insets).adrenal gland, salivary gland, breast, ovary, uterus, pros-tate, bladder, colon, stomach, pancreas, lung, kidney,
liver, parathyroid gland, thyroid gland, testis, and brain
was stained for CD137. No significant CD137 expression
was observed in any of these nonhematopoietic tissues
(see Supplemental Table S1 at http://ajp.amjpathol.org).
Although previous reports identified CD137 expression in
intratumoral blood vessels,23 we did not detect signifi-
cant CD137 expression by endothelial cells in either neo-
plastic or normal tissue.
CD137 Is Expressed by Follicular Dendritic Cell
Neoplasms
Dendritic and histiocytic cell tumors are a heterogeneous
group of neoplasms that are often difficult to diagnose
solely by morphological criteria. Because CD137 was
strongly expressed by normal FDCs, we investigated the
expression of CD137 across a diverse group of histio-
cytic and dendritic cell neoplasms by immunohistochem-
istry. We found strong and consistent cytoplasmic and
cell membrane expression of CD137 in FDC neoplasms,
confirming that CD137 expression is maintained during
neoplastic transformation (Figure 2A and Table 1). In our
series, an equivalent number of cases were positive for
Figure 2. CD137 is expressed by FDC tumors and classical Hodgkin lym-
phoma. A–D: Immunohistochemical stain for CD137 on paraffin-embedded
tissue sections of FDC tumor (A), Langerhans cell histiocytosis (LCH) (B),
classical Hodgkin lymphoma (CHL) (C), and nodular lymphocyte predomi-
nant Hodgkin lymphoma (NLPHD) (D). E and F: Sections of classical Hodg-
kin lymphoma stained with antibodies to CD137 (red; cytoplasm and cell
membrane) and CD3 (green; cell membrane); DAPI (blue) was used as a
nuclear counterstain. G: Section of classical Hodgkin lymphoma stained with
antibodies to CD137 (red; cytoplasm and cell membrane) and CD3 (green;
cell membrane), with DAPI (blue) as a nuclear counterstain, visualized using
confocal microscopy. Original magnification: 400 (A–G); 900 (inset, C);
600 (inset, D).
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positive but CD21 and CD23 were focal or negative,
suggesting that CD137 may be a useful adjunct marker to
diagnose FDC tumors in the absence of CD21 and CD23
staining. In contrast, CD137 expression was not ob-
served in other histiocytic neoplasms, including Langer-
hans cell histiocytosis (Figure 2B) and interdigitating den-
dritic cell tumor (Table 1). Other spindle cell neoplasms,
such as dermatofibrosarcoma protuberans and leiomyo-
sarcoma, failed to stain with CD137 (see Supplemental
Table S1 at http://ajp.amjpathol.org). One case of blastic
plasmacytoid dendritic cell tumor showed weak positive
staining for CD137 (Table 1). CD137 was not expressed
in any subtype of acute myeloid leukemia that was eval-
uated (Table 1). Reactive histiocytic proliferations such
as Rosai-Dorfman disease also failed to express CD137
(Table 1).
CD137 Is a Marker of Classical Hodgkin
Lymphoma
TMAs and whole-tissue sections were used to investigate
the expression of CD137 in both classical Hodgkin lym-
phoma (CHL, 208 cases) and nodular lymphocyte pre-
dominant Hodgkin lymphoma (NLPHL, 17 cases). We
found expression of CD137 protein in the Hodgkin and
Reed-Sternberg cells of 179/208 (86%) CHL cases (Fig-
ure 2C and Table 1). By immunohistochemistry, CD137
staining was localized to the membrane and cytoplasm,
often with punctate paranuclear staining similar to the
typical pattern of reactivity of CD15 (Figure 2C). CD137
was also expressed in a considerable proportion of
cases that lacked CD15 staining (63/80, or 79%), sug-
gesting that CD137 is a useful additional marker for CHL
diagnosis with lacking CD15 expression (see Supple-
mental Table S2 at http://ajp.amjpathol.org). CD137 was
frequently coexpressed with CD30 (176/197, 89%), but
CD137 expression did not correlate with the presence of
Epstein-Barr virus (EBV) as identified by in situ hybridiza-
tion for EBER RNA (P  0.98). The expression of CD137
did not correlate with overall survival (P  0.504) or
progression-free survival (P  0.235) in our series of
cases (see Supplemental Figures S1 and S2 at http://
ajp.amjpathol.org). In cases of NLPHL, CD137 highlighted
the expanded and disrupted FDC networks that are often
prominent in this diagnosis (Figure 2D), but the atypical
lymphocyte predominant cells (Figure 2D, inset) failed to
Table 2. Immunohistochemical Characterization of Follicular
Dendritic Cell Tumors
Case CD137 CD21 CD23 CD35
1    (weak) n/d
2   (focal)  
3     (weak)
4   n/d 
5  (weak)  n/d n/d
6    
7    
n/d, not done.stain for CD137. Immunofluorescence staining of CD137showed crisp membranous localization with faint cyto-
plasmic and strong paranuclear staining when visualized
using either standard (Figure 2, E and F) or confocal
microscopy (Figure 2G). Very little CD137 staining was
observed in the background cellular infiltrate, including
infiltrating T lymphocytes (Figure 2, F and G).
CD137 Expression by Non-Hodgkin B-Cell
Lymphoma Tumor Cells
We next asked whether CD137 was expressed by other
tumors of the lymphoid lineage, in a broad survey of 359
non-Hodgkin B-cell lymphomas and 158 plasma cell neo-
plasms (Table 1). In contrast to the frequent expression of
CD137 in CHL, no significant CD137 expression was
detected in immature B-cell tumors or the majority of
mature B-cell lymphomas, including follicular lymphoma
(Figure 3A), DLBCL (Figure 3B), and chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL; Figure
Figure 3. CD137 expression by B-, T-, and NK-cell-derived lymphomas.
Immunohistochemical stains for CD137 on paraffin-embedded tissue sec-
tions of follicular lymphoma (FL) (A), diffuse large B-cell lymphoma (DLBCL)
(B), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)
(C) show lack of expression of CD137 in tumor cells. In contrast to B-cell
lymphomas, peripheral T-cell lymphoma not otherwise specified (PTCL) (D),
angioimmunoblastic T-cell lymphoma (AITL) (E), ALK anaplastic large cell
lymphoma (ALCL) (F), CD30 mycosis fungoides (MF) (G), and extranodal
NK/T-cell lymphoma, nasal type (NK) (H), show tumor cell staining for
CD137. Original magnification, 400.
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marginal zone lymphoma, mantle cell lymphoma, or
plasma cell neoplasms (Table 1). In contrast, we ob-
served CD137 expression in a subset of cases of primary
mediastinal large B-cell lymphoma (PMBL) (7/46, or 15%;
Table 1). Of note, CD137 staining in the positive cases of
PMBL highlighted large atypical Hodgkin-appearing cells
but not all lymphoma cells within the biopsy specimen.
Because PMBL and CHL share overlapping morpholog-
ical, immunophenotypic, and molecular features, we
stained an additional 10 cases of B-cell lymphoma, un-
classifiable, with features intermediate between diffuse
large B-cell lymphoma and classical Hodgkin lymphoma
(BCLU/DLBCL/CHL), a new WHO 2008 diagnostic cate-
gory that was created to formally recognize and better
define cases exhibiting overlap between those two cate-
gories (the so-called gray-zone lymphoma).29,30 Notably,
we observed CD137 expression in 5 of 10 (50%) of these
cases (Table 1; see also Supplemental Figure S3 at
http://ajp.amjpathol.org).
Although CD137 was not found in the majority of B-cell
lymphomas, CD137-expressing cells were detected
within the tumor microenvironment. The number of
CD137 cells was generally low, representing 10% of
the total tissue cellularity. Among DLBCL cases, 62%
showed CD137 infiltrating cells, possibly representing
infiltrating T cells or other stromal components. Among
follicular lymphomas, 72% of cases showed CD137
cells within the neoplastic follicles, with residual FDC
networks contributing to the overall staining pattern.
Among cases of marginal zone and mantle cell lym-
phoma, a similar proportion (61% and 50%, respectively)
showed CD137 cells within the microenvironment, but
significantly fewer cases (17%) of CLL/SLL showed
CD137 cells in the microenvironment (data not shown).
The absence of CD137 expression in tumor B cells of
these non-Hodgkin B-cell lymphoma was confirmed also
by flow cytometry (data not shown).
CD137 Is Expressed by a Subset of T-Cell and
NK/T-Cell Lymphomas
In contrast to non-Hodgkin B-cell lymphomas, approxi-
mately 58% of T-cell lymphomas showed immunoreactiv-
ity for CD137. CD137 was expressed across multiple
histological subtypes of mature T-cell lymphomas, in-
cluding PTCL NOS (Figure 3D), AITL (Figure 3E), ALK
anaplastic large cell lymphoma (Figure 3F), and mycosis
fungoides (Figure 3G). CD137 was not expressed by
immature T-cell lymphomas. Double-immunofluores-
cence labeling of select PTCL and AITL cases confirmed
coexpression of CD3 and CD137 on the lesional cells
(see Supplemental Figure S4 at http://ajp.amjpathol.org).
Approximately 37% of cases of extranodal NK/T-cell lym-
phoma, nasal type, also expressed CD137 (Figure 3H).
CD137 staining of NK/T-cell neoplasms tended to be less
intense than CHL or T-cell lymphoma.
Although we observed tumor cell expression of CD137
by immunohistochemistry, we next asked whether we
could detect cell-surface expression of CD137 on unfixedtumor cells by flow cytometry, to ascertain the possible
efficacy of anti-CD137 antibody therapy or risk for pro-
moting tumor growth with agonistic anti-CD137 antibody
therapy; the latter antibody is currently in clinical trials as
BMS-663513 (http://www.clinicaltrials.gov). Flow cytom-
etry confirmed that CD137 is indeed expressed on the
cell surface as illustrated in a case of ALK anaplastic
large cell lymphoma (Figure 4). This T-cell lymphoma
showed effacement of the lymph node architecture by an
atypical and a pleomorphic large cell infiltrate associated
with eosinophilia and a prominent vascular proliferation.
By immunohistochemistry, the tumor cells expressed
CD3, CD8, CD30 (diffuse and strong expression), and
CD137, but lacked expression of CD20, CD4, CD15, and
ALK1 (Figure 4, A–F). By flow cytometry gating on the
large-cell subset to enrich for the neoplastic cells, ap-
proximately 18% of the CD3CD8 tumor cells ex-
pressed CD137 (Figure 4G), confirming the presence of
CD137 protein on the tumor cell membrane.
Discussion
The expression of CD137 protein in both normal and
neoplastic human lymphoid tissue is important to evalu-
ate, because its cell- and tissue-specific expression pat-
terns are likely to influence the choice and usage of
Figure 4. Detection of tumor cell CD137 expression by flow cytometry. A–F:
A case of ALK anaplastic large cell lymphoma was stained with H&E (A)
and antibodies to CD8 (B), CD4 (C), CD30 (D), ALK1 (E), and CD137 (F). The
lymphoma cells showed positivity for CD8, CD30, and CD137. G: Flow
cytometric evaluation of CD137 expression showed lack of CD137 expres-
 sion by CD20 B cells and CD4 T cells, but detectable expression of CD137
in a proportion (18.5 %) of CD8 tumor T cells. Original magnification,600.
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sil and lymph node, we found that CD137 is a specific
marker of FDCs. In contrast, we observed very little ex-
pression of CD137 protein by T and B cells within normal
tonsil, spleen, and thymus. Pauly et al7 found a similar
pattern of CD137 reactivity in normal human lymph nodes
using the same monoclonal antibody on frozen tissue
sections. Thus, the specificity of CD137 reactivity we
observed in the present study is not an artifact of tissue
processing. Such a restricted pattern of CD137 protein
expression supports the hypothesis that CD137 is likely
to be an important regulator of FDC and B-cell interac-
tions during the GC reaction.7 CD137 expression by
FDCs could therefore also be considered a part of the
normal GC signature, along with B-cell-specific markers
such as LMO2, BCL-6, and CD10 and T-cell-specific
markers such as PD-1 and CXCL13.
We also demonstrated that CD137 is a highly spe-
cific immunohistochemical marker of neoplastic FDCs.
FDC tumors are uncommon hematopoietic neoplasms
and are often overlooked in the histological differential
diagnosis of spindle-cell tumors. CD137 strongly
stained the majority of FDC tumors in our series, indi-
cating that CD137 immunohistochemistry is a useful
diagnostic marker of FDC tumors (along with CD21,
CD23, and podoplanin).31,32
Perhaps the most novel finding of the present study
was the expression of CD137 in a significantly high pro-
portion of CHL samples. Although CD137 expression has
been previously detected in cultured CHL cells,33 to our
knowledge this is the first report describing CD137 ex-
pression in primary CHL samples. CD137 immunohisto-
chemistry may be particularly helpful for cases of CHL
with weak or absent expression of the typical diagnostic
markers (CD30, CD15, and paired box protein Pax-5). In
such cases, the differential diagnosis includes entities
such as NLPHL, CD30 B-cell lymphoma, and T-cell
lymphoma, each with a markedly different prognosis and
treatment. Although CD137 expression may not entirely
exclude T-cell lymphoma from the differential diagnosis,
our results suggest that CD137 would serve as an excel-
lent adjunct marker on the immunohistologic panel used
to rule out a diagnosis of NLPHL. Among large B-cell
lymphomas, the expression of CD137 in a subset of
PMBL and the new WHO 2008 category of BCLU/DLBCL/
CHL further underscores the molecular overlap among
PMBL, CHL, and BCLU/DLBCL/CHL. Although CD137
expression does not appear to resolve the diagnostic
dilemma posed by gray-zone B-cell lymphomas of the
mediastinum, its expression may represent a novel ther-
apeutic strategy for the management of these tumors,
particularly BCLU/DLBCL/CHL tumors, which typically
exhibit a poor clinical outcome.34 Although CD137 is a
useful diagnostic marker for CHL, in our series of cases it
was not significantly associated with overall survival or
progression-free survival.
Although there is much evidence to support the GC
B-cell derivation of CHL,35,36 a subset of CHL cases have
also been reported to express T-cell markers37,38 and
FDC markers.39 Although the expression of non-B-cell
antigens may be a consequence of transcriptional dys-regulation during neoplastic transformation,40 another
possibility is that CD137 expression by CHL is evidence
of heterotopic intracellular fusion between FDCs and GC
B cells. This hypothesis would explain the frequent find-
ing of binucleated (Hodgkin/Reed-Sternberg) cells in
CHL and the relative lack of expression of B-cell markers
such as CD20. However, experiments designed to detect
molecular evidence of cell fusion events in CHL suggest
that binucleated CHL cells derive from endomitosis,
rather than from cellular fusion.41
CD137 is also expressed in a significant proportion of
T- and NK-cell-derived lymphomas. In the present study,
CD137 expression was not specific for the histological
subtype of mature T-cell lymphoma, consistent with the
broad expression pattern of CD137 by normal mature
T-cell subsets.11 We also observed CD137 expression in
a significant proportion of cases of extranodal NK/T-cell
lymphoma, nasal type, although the staining was gener-
ally weaker in intensity. Although the effect of CD137
signaling to promote T-cell proliferation and survival is
well studied, much less is known about the biological role
of CD137 expression by normal human NK cells. Further
experiments are required to address the functional sig-
nificance of CD137 expression by either T-cell or NK-cell
neoplasms.
Consistent with the lack of expression of CD137 by
normal B cells, we did not observe CD137 expression by
the majority of non-Hodgkin B-cell lymphomas. However,
we did observe that a significant proportion of B-cell
lymphomas showed increased numbers of infiltrating
CD137 cells in the tumor microenvironment. Although it
is difficult to phenotype these cells using immunohisto-
chemistry, members of our research group have identi-
fied increased numbers of CD137 T cells in follicular
lymphoma, mantle cell lymphoma, and DLBCL using flow
cytometry with a different anti-CD137 monoclonal anti-
body (clone 4B4-1).18 FDCs are difficult to analyze using
flow cytometry, but our immunohistochemical data sug-
gest that FDCs may also contribute to the expression of
CD137 in the microenvironment of B-cell lymphomas.
Further experiments are required to address the role of
CD137/CD137L interactions in the tumor microenviron-
ment, to fully understand the role of this receptor-ligand
pair in B-cell neoplasia.
Our observation that select subtypes of lymphoma ex-
press CD137 has significant implications for the use of
anti-CD137 immunotherapy. To date, only agonistic anti-
CD137 monoclonal antibodies have been tested in pre-
clinical models and small phase 1 clinical trials.42 In this
therapeutic strategy, stimulation of CD137 on T cells via
agonistic anti-CD137 antibody results in T-cell activation,
proliferation, and enhancement of anti-tumor immunity.
However, our observation that CHL, FDC tumors, T-cell
lymphoma, extranodal NK/T-cell lymphoma, PMBL, and
BCLU/DLBCL/CHL can all express CD137 raises the
possibility that these tumor subtypes could be directly
targeted by anti-CD137 antibodies. Although humanized
antagonistic anti-CD137 monoclonal antibodies have
been developed,43,44 to our knowledge these reagents
have not been developed as possible therapeutic
agents. Perhaps this is not surprising, given the lack of
802 Anderson et al
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human solid-organ tumors.23,45 Detection of CD137 on
the cell membranes of unfixed neoplastic T cells by flow
cytometry is encouraging in that CD137 could indeed
function as a therapeutic target in patients with lym-
phoma subtypes that express CD137. Additional exper-
iments are required to assess whether CD137 represents
a useful therapeutic target on patients with CD137 lym-
phoma subtypes.
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